开云app官网登录入口网页版-官方正版

#头对头#

34篇内容 | 1504人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1949833, encodeId=cf3919498335d, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, objectTitle=周清教授 | 首个PD-1抑制剂头对头研究结果在2022 ASCO公布，中国创新药物彰显实力, objectType=article, longId=731997, objectId=1efbe3199786, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1efbe3199786, replyNumber=0, likeNumber=88, createdTime=2022-11-21, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1efbe3199786, moduleTitle=周清教授 | 首个PD-1抑制剂头对头研究结果在2022 ASCO公布，中国创新药物彰显实力, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1efbe3199786)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949831, encodeId=7a96194983164, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, objectTitle=NEJM：头对头研究证实mRNA-1273疫苗的有效性优于BNT162b2疫苗, objectType=article, longId=294144, objectId=f46229414423, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f46229414423, replyNumber=0, likeNumber=99, createdTime=2022-10-19, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f46229414423, moduleTitle=NEJM：头对头研究证实mRNA-1273疫苗的有效性优于BNT162b2疫苗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f46229414423)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949832, encodeId=36dc1949832b1, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, objectTitle=Lancet：乌司奴单抗 vs 阿达木单抗治疗克罗恩病头对头研究结果出炉, objectType=article, longId=729675, objectId=dbcee2967524, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbcee2967524, replyNumber=0, likeNumber=82, createdTime=2023-05-03, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbcee2967524, moduleTitle=Lancet：乌司奴单抗 vs 阿达木单抗治疗克罗恩病头对头研究结果出炉, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=dbcee2967524)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949828, encodeId=76911949828ee, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, objectTitle=Alzheimer&Dementia：AD患者脑脊液p-tauT181和T217的临床诊断头对头比较, objectType=article, longId=214048, objectId=c0f0214048b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0f0214048b1, replyNumber=0, likeNumber=78, createdTime=2022-06-14, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0f0214048b1, moduleTitle=Alzheimer&Dementia：AD患者脑脊液p-tauT181和T217的临床诊断头对头比较, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c0f0214048b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949830, encodeId=bc461949830a1, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, objectTitle=Ther Adv Med Oncol：国内多中心头对头III期研究发现转移性结直肠癌患者二线FOLFIRI方案并不优于单药伊立替康治疗，反而毒性增加, objectType=article, longId=294046, objectId=01c32940469c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01c32940469c, replyNumber=0, likeNumber=88, createdTime=2022-06-18, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01c32940469c, moduleTitle=Ther Adv Med Oncol：国内多中心头对头III期研究发现转移性结直肠癌患者二线FOLFIRI方案并不优于单药伊立替康治疗，反而毒性增加, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=01c32940469c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949827, encodeId=55b2194982eb3, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, objectTitle=SoliMix结果公布：基础胰岛素与GLP-1RA的复方制剂与预混胰岛素的头对头比较研究, objectType=article, longId=213502, objectId=ee6b2135028f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee6b2135028f, replyNumber=0, likeNumber=96, createdTime=2022-03-04, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee6b2135028f, moduleTitle=SoliMix结果公布：基础胰岛素与GLP-1RA的复方制剂与预混胰岛素的头对头比较研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ee6b2135028f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949825, encodeId=a1341949825ed, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, objectTitle=阿卡替尼 vs. 伊布替尼治疗CLL头对头试验达到主要疗效终点, objectType=article, longId=206320, objectId=9bfb2063201f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bfb2063201f, replyNumber=0, likeNumber=104, createdTime=2021-12-30, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bfb2063201f, moduleTitle=阿卡替尼 vs. 伊布替尼治疗CLL头对头试验达到主要疗效终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9bfb2063201f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949826, encodeId=d22e194982692, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, objectTitle=NEJM：Tirzepatide头对头III期研究成功降糖减重效果优于索马鲁肽, objectType=article, longId=213588, objectId=8938213588ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8938213588ec, replyNumber=0, likeNumber=78, createdTime=2021-11-13, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8938213588ec, moduleTitle=NEJM：Tirzepatide头对头III期研究成功降糖减重效果优于索马鲁肽, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8938213588ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949829, encodeId=6f8619498299a, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, objectTitle=JAMA Neuro：哪种更有效？老年痴呆8种血浆淀粉样β42/40检测方法的头对头比较, objectType=article, longId=217456, objectId=09f021e456e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09f021e456e4, replyNumber=0, likeNumber=82, createdTime=2022-08-23, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09f021e456e4, moduleTitle=JAMA Neuro：哪种更有效？老年痴呆8种血浆淀粉样β42/40检测方法的头对头比较, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=09f021e456e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949824, encodeId=7cc61949824d3, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, objectTitle=NEJM：“头对头”III期研究证实治疗ALK阳性非小细胞肺癌，劳拉替尼显著优于克唑替尼, objectType=article, longId=203570, objectId=632d2035e081, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=632d2035e081, replyNumber=0, likeNumber=86, createdTime=2021-09-22, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=632d2035e081, moduleTitle=NEJM：“头对头”III期研究证实治疗ALK阳性非小细胞肺癌，劳拉替尼显著优于克唑替尼, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=632d2035e081)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949823, encodeId=80601949823a5, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, objectTitle=头对头3期临床证实：抗IL-17单抗Bimekizumab治疗中度至重度银屑病优于TNF单抗修美乐, objectType=article, longId=202790, objectId=00a7202e904b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00a7202e904b, replyNumber=0, likeNumber=76, createdTime=2021-02-12, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00a7202e904b, moduleTitle=头对头3期临床证实：抗IL-17单抗Bimekizumab治疗中度至重度银屑病优于TNF单抗修美乐, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=00a7202e904b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949817, encodeId=40e6194981e08, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, objectTitle=头对头临床试验：百济神州的BTK抑制剂Brukinsa未能击败强生/艾伯维的Imbruvica, objectType=article, longId=184955, objectId=41c3184955ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41c3184955ce, replyNumber=0, likeNumber=88, createdTime=2020-10-01, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41c3184955ce, moduleTitle=头对头临床试验：百济神州的BTK抑制剂Brukinsa未能击败强生/艾伯维的Imbruvica, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=41c3184955ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949821, encodeId=846319498213d, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, objectTitle=EHA 2020：III期头对头研究证实C3补体抑制剂pegcetacoplan治疗阵发性夜间血红蛋白尿疗效显著, objectType=article, longId=195820, objectId=4ad419582055, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ad419582055, replyNumber=0, likeNumber=82, createdTime=2020-12-07, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ad419582055, moduleTitle=EHA 2020：III期头对头研究证实C3补体抑制剂pegcetacoplan治疗阵发性夜间血红蛋白尿疗效显著, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4ad419582055)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949819, encodeId=e8c619498196e, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, objectTitle=EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept, objectType=article, longId=195490, objectId=a38e195490b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a38e195490b9, replyNumber=0, likeNumber=74, createdTime=2021-05-16, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a38e195490b9, moduleTitle=EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a38e195490b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949822, encodeId=b094194982236, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, objectTitle=SKYRIZI（risankizumab-rzaa）与COSENTYX（secukinumab）头对头研究：SKYRIZI优势显著, objectType=article, longId=195876, objectId=4d741958e69f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d741958e69f, replyNumber=0, likeNumber=72, createdTime=2020-12-13, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d741958e69f, moduleTitle=SKYRIZI（risankizumab-rzaa）与COSENTYX（secukinumab）头对头研究：SKYRIZI优势显著, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4d741958e69f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949820, encodeId=926d194982030, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, objectTitle=DDW 2020：伏诺拉生 vs. 兰索拉唑对十二指肠溃疡的疗效头对头研究, objectType=article, longId=195491, objectId=abe819549102, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abe819549102, replyNumber=0, likeNumber=89, createdTime=2020-07-20, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abe819549102, moduleTitle=DDW 2020：伏诺拉生 vs. 兰索拉唑对十二指肠溃疡的疗效头对头研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=abe819549102)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949818, encodeId=a866194981854, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, objectTitle=头对头牛皮癣临床研究，艾伯维的IL-23单抗Skyrizi显着优于诺华的IL-17单抗Cosentyx, objectType=article, longId=186385, objectId=ced718638553, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ced718638553, replyNumber=0, likeNumber=71, createdTime=2020-07-06, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ced718638553, moduleTitle=头对头牛皮癣临床研究，艾伯维的IL-23单抗Skyrizi显着优于诺华的IL-17单抗Cosentyx, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ced718638553)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949815, encodeId=66ed1949815df, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, objectTitle=银屑病关节炎头对头实验中，诺华的IL-17单抗Cosentyx与Humira相比未能实现统计学意义的改善, objectType=article, longId=182337, objectId=c39f18233ed9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c39f18233ed9, replyNumber=0, likeNumber=92, createdTime=2019-12-14, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c39f18233ed9, moduleTitle=银屑病关节炎头对头实验中，诺华的IL-17单抗Cosentyx与Humira相比未能实现统计学意义的改善, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c39f18233ed9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949814, encodeId=4c901949814eb, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, objectTitle=头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率, objectType=article, longId=180571, objectId=711e1805e121, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=711e1805e121, replyNumber=0, likeNumber=62, createdTime=2020-06-10, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=711e1805e121, moduleTitle=头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=711e1805e121)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949813, encodeId=37cc194981326, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, objectTitle=《新英格兰医学杂志》发表针对溃疡性结肠炎的首项头对头临床研究，强调了维多珠单抗与阿达木单抗相比的优越性, objectType=article, longId=180090, objectId=e422180090fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e422180090fa, replyNumber=0, likeNumber=85, createdTime=2019-11-19, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e422180090fa, moduleTitle=《新英格兰医学杂志》发表针对溃疡性结肠炎的首项头对头临床研究，强调了维多珠单抗与阿达木单抗相比的优越性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e422180090fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

头对头

2020-05-29

朱睿睿 (审核中...)

前往app查看评论内容

#头对头#

周清教授 | 首个PD-1抑制剂头对头研究结果在2022 ASCO公布，中国创新药物彰显实力

2022-11-21

朱睿睿 (审核中...)

前往app查看评论内容

#头对头#

NEJM：头对头研究证实mRNA-1273疫苗的有效性优于BNT162b2疫苗

2022-10-19

朱睿睿 (审核中...)

前往app查看评论内容

#头对头#

Lancet：乌司奴单抗 vs 阿达木单抗治疗克罗恩病头对头研究结果出炉

2023-05-03

朱睿睿 (审核中...)

前往app查看评论内容

#头对头#

Alzheimer&Dementia：AD患者脑脊液p-tauT181和T217的临床诊断头对头比较

2022-06-14

朱睿睿 (审核中...)

前往app查看评论内容

#头对头#

Ther Adv Med Oncol：国内多中心头对头III期研究发现转移性结直肠癌患者二线FOLFIRI方案并不优于单药伊立替康治疗，反而毒性增加

2022-06-18

朱睿睿 (审核中...)

前往app查看评论内容

#头对头#

SoliMix结果公布：基础胰岛素与GLP-1RA的复方制剂与预混胰岛素的头对头比较研究

2022-03-04

朱睿睿 (审核中...)

前往app查看评论内容

#头对头#

阿卡替尼 vs. 伊布替尼治疗CLL头对头试验达到主要疗效终点

2021-12-30

一叶知秋 (审核中...)

前往app查看评论内容

#头对头#

NEJM：Tirzepatide头对头III期研究成功降糖减重效果优于索马鲁肽

2021-11-13

朱睿睿 (审核中...)

前往app查看评论内容

#头对头#

JAMA Neuro：哪种更有效？老年痴呆8种血浆淀粉样β42/40检测方法的头对头比较

2022-08-23

朱睿睿 (审核中...)

前往app查看评论内容

#头对头#

NEJM：“头对头”III期研究证实治疗ALK阳性非小细胞肺癌，劳拉替尼显著优于克唑替尼

2021-09-22

朱睿睿 (审核中...)

前往app查看评论内容

#头对头#

头对头3期临床证实：抗IL-17单抗Bimekizumab治疗中度至重度银屑病优于TNF单抗修美乐

2021-02-12

朱睿睿 (审核中...)

前往app查看评论内容

#头对头#

头对头临床试验：百济神州的BTK抑制剂Brukinsa未能击败强生/艾伯维的Imbruvica

2020-10-01

朱睿睿 (审核中...)

前往app查看评论内容

#头对头#

EHA 2020：III期头对头研究证实C3补体抑制剂pegcetacoplan治疗阵发性夜间血红蛋白尿疗效显著

2020-12-07

朱睿睿 (审核中...)

前往app查看评论内容

#头对头#

EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept

2021-05-16

朱睿睿 (审核中...)

前往app查看评论内容

#头对头#

SKYRIZI（risankizumab-rzaa）与COSENTYX（secukinumab）头对头研究：SKYRIZI优势显著

2020-12-13

朱睿睿 (审核中...)

前往app查看评论内容

#头对头#

DDW 2020：伏诺拉生 vs. 兰索拉唑对十二指肠溃疡的疗效头对头研究

2020-07-20

朱睿睿 (审核中...)

前往app查看评论内容

#头对头#

头对头牛皮癣临床研究，艾伯维的IL-23单抗Skyrizi显着优于诺华的IL-17单抗Cosentyx

2020-07-06

朱睿睿 (审核中...)

前往app查看评论内容

#头对头#

银屑病关节炎头对头实验中，诺华的IL-17单抗Cosentyx与Humira相比未能实现统计学意义的改善

2019-12-14

朱睿睿 (审核中...)

前往app查看评论内容

#头对头#

头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率

2020-06-10

朱睿睿 (审核中...)

前往app查看评论内容

#头对头#

《新英格兰医学杂志》发表针对溃疡性结肠炎的首项头对头临床研究，强调了维多珠单抗与阿达木单抗相比的优越性

2019-11-19

科室
- - 订阅+
  - 更多科室
工具
服务